Please ensure Javascript is enabled for purposes of website accessibility

4 Growth Stocks You Can Safely Hold Through 2030

By Sean Williams – Oct 14, 2020 at 6:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These high-growth companies offer competitive advantages that'll favor buy-and-hold investors.

It's a debate nearly as old as the stock market itself: Growth versus value.

A 2016 analysis by Bank of America/Merrill Lynch gives the nod to value stocks, although both types of stocks have performed exceptionally well. Between 1926 and 2015, BofA found that value stocks outperformed growth stocks on an annual average basis (17% vs. 12.6%).

However, growth stocks have wildly outperformed value stocks since the Great Recession. This is likely in part due to historically low lending rates fueling borrowing, hiring, acquisitions, and innovation. With interest rates likely to remain well below their historical average throughout the 2020s, growth stocks could be a smart place to park your money over the next decade.

The following four growth stocks represent rock-solid companies that I believe you can safely hold through 2030.

A businessperson holding a stopwatch above an ascending stack of coins.

Image source: Getty Images.


In the past few months, social media giant Facebook (META -0.74%) faced advertising boycotts over its hate-speech oversight, as well as a recent report from the House Judiciary Subcommittee on Antitrust, Commercial, and Administrative Law that accused it of holding monopoly power.

This is par for the course when you're the most dominant social media platform. 

Facebook ended June with 2.7 billion monthly active users (MAU), or 3.14 billion MAUs if you include family sites like Instagram and WhatsApp. Advertisers are aware that there's no other social platform they can go to where they're going to reach up to 3 billion targeted pairs of eyeballs. This is what gives Facebook such incredible and lasting pricing power on its ads.

Facebook is arguably still in the early to middle innings of its growth phase. While that might be hard to believe for a company already valued at $753 billion, Facebook hasn't yet monetized Facebook Messenger or WhatsApp in any meaningful way. Facebook owns four of the six most widely used social platforms in the world, but has only truly monetized two of them. This suggests Facebook's growth runway should extend throughout the 2020s. 

A computer monitor displaying a patient's vital signs in an operating room.

Image source: Getty Images.

Intuitive Surgical

Precision medicine is going to be the single greatest growth driver in the healthcare space over the next decade, and I have no doubt in my mind that surgical system developer Intuitive Surgical (ISRG 0.26%) will benefit big time from it.

Intuitive Surgical is the company behind the da Vinci surgical system, which is used in a variety of soft tissue surgeries to make smaller and more precise incisions that heal more quickly, shortening hospital stays.

Intuitive Surgical's da Vinci system is the undisputed leader in robotic-assisted surgical procedures. The company had more than 5,700 of its machines installed worldwide as of June 2020, which is more than any of its competitors on a combined basis. Its competitive advantage appears safe.

Furthermore, investors should fully expect Intuitive Surgical's bottom-line expansion to outpace sales growth throughout the decade. Selling procedure-specific instruments and maintenance services generates much juicier margins for the company than the da Vinci systems themselves, which are costly to build. As the company's installed base expands, we can expect a growing percentage of total sales to derive from these higher-margin segments.

A lab researcher looking at a clipboard while holding a vial of blood.

Image source: Getty Images.

Vertex Pharmaceuticals

Usually, novel drugmakers in the biotech space wouldn't be considered safe haven investments over a full decade. After all, brand-name drugs have finite periods of patent exclusivity that threaten their long-term cash flow potential. But Vertex Pharmaceuticals (VRTX -1.01%) looks to be an exception to the rule.

Vertex Pharmaceuticals is the leading drug developer for patients with cystic fibrosis. CF is a hereditary disease that produces thick mucus that can obstruct a patients' lungs and pancreas. Though there's no cure, Vertex's products for specific CF mutations are improving the lives of patients.

The company's newest approved CF drug, Trikafta, led to a 3.7-percentage-point improvement relative to a placebo in an airway obstruction metric often used to evaluate therapeutic efficacy. It also met all of its secondary endpoints in a late-stage trial. Perhaps it's no surprise that the Food and Drug Administration gave it the green light five months ahead of schedule -- or that, after two full quarters on pharmacy shelves, Trikafta has already achieved blockbuster status (i.e., greater than $1 billion in annual sales). 

Vertex's innovation and focus on specific CF mutations will protect its cash flow and allow for double-digit growth potential through at least 2030.

Two college students sharing a laptop.

Image source: Getty Images.


Even though it's been hit harder than other FAANG stocks during the coronavirus recession, Alphabet (GOOGL -1.02%) (GOOG -1.24%) is a growth stock investors can safely buy and hang onto through 2030, if not well beyond.

Alphabet is the parent company of Google, the most dominant Internet search platform in the world. According to data from StatCounter Global Stats, Google has maintained between 91.9% and 93% of global search market share over the trailing year. Just as Facebook is the unquestioned go-to for social media advertising, Google is the clear leader for search-based ad placement, and that's not going to change anytime soon.

However, Alphabet is more than just search these days. YouTube has become one of the three most visited social websites in the world, driving the company's ad growth. We're also witnessing exceptionally fast growth from cloud infrastructure segment Google Cloud, which topped $3 billion in quarterly revenue for the first time during the pandemic-challenged second quarter. The high margins generated from Google Cloud should allow Alphabet's cash flow to catapult higher by mid-decade.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Sean Williams owns shares of Bank of America, Facebook, and Intuitive Surgical. The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), Facebook, and Intuitive Surgical. The Motley Fool recommends Vertex Pharmaceuticals and recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alphabet (A shares) Stock Quote
Alphabet (A shares)
$97.46 (-1.02%) $-1.00
Meta Platforms, Inc. Stock Quote
Meta Platforms, Inc.
$111.41 (-0.74%) $0.83
Intuitive Surgical Stock Quote
Intuitive Surgical
$265.13 (0.26%) $0.68
Vertex Pharmaceuticals Stock Quote
Vertex Pharmaceuticals
$312.98 (-1.01%) $-3.18
Alphabet (C shares) Stock Quote
Alphabet (C shares)
$97.60 (-1.24%) $-1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.